DP
SUPN icon

Diadema Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Diadema Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-22,348
Closed -$1.07M – 195
2025
Q3 		$1.07M Buy
+22,348
New +$900K 0.27% 85

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Diadema Partners's SUPN Position: Q4 2025 in Review

Diadema Partners sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 22,348 shares — an estimated $1.07M sold.

Diadema Partners first reported a position in SUPN in Q3 2025 and held it in 1 quarter. The position peaked at $1.07M in Q3 2025. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • Diadema Partners reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Diadema Partners sold 22,348 Supernus Pharmaceuticals shares in Q4 2025, an estimated $1.07M.
  • Diadema Partners first reported a position in Supernus Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Diadema Partners's Supernus Pharmaceuticals position peaked at $1.07M in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.